Sorry!! The article you are trying to read is not available now.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Halozyme Therapeutic (NQ: HALO)
16.51 USD  +0.16 (+0.98%)
Official Closing Price  /  Updated: 5:07 PM EDT, Sep 17, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 805,100
Open 16.32
Bid (Size) 14.50 (4)
Ask (Size) 18.00 (5)
Prev. Close 16.35
Today's Range 16.16 - 16.60
52wk Range 13.24 - 18.76
Shares Outstanding 143,965,620
Dividend Yield N/A
Performance
YTD
+11.55%
+11.55%
1 Month
-1.02%
-1.02%
3 Month
+0.30%
+0.30%
6 Month
-1.37%
-1.37%
1 Year
-1.02%
-1.02%
Featured News
More News
Volatility Index signals that the bull has room to run
The Volatility Index has yet to reach complacent extremes, suggesting that the U.S. markets’ 2015 rally has room to run. Read More
category Mining and Metals , Banks , Retail , and 24 more.
from MarketWatch
Ciena Corp. jumps on earnings; PVH sinks
Ciena Corp. is up sharply on earnings while PVH Corp, which owns Calvin Klein, sinks on results. Read More
category HALO , Computer Hardware , Commodities , and 20 more.
from MarketWatch
Featured News
Read More
Friday’s biggest gaining and declining stocks
category Software , Markets/Exchanges , NKE , and 20 more.
from MarketWatch
Friday’s biggest gaining and declining stocks
category ASTX , Market News , Commodities , and 10 more.
from MarketWatch
Thursday's biggest gaining and declining stocks
category General , SNTS , MW , and 3 more.
from MarketWatch
Drug stocks retreat with broader market
category $BTK , MRK , Company Announcements , and 8 more.
from MarketWatch
More News
Read More
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
from PR Newswire
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference
from PR Newswire
Halozyme Reports Second Quarter 2019 Results
from PR Newswire
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference
from PR Newswire
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
from PR Newswire
REPEAT/Halo Announces the Launch of XES Sensual, a Unique CBD Sexual Wellness Product Continues Company Trend of Product Innovation in Growing Category
from Business Wire News Releases
Halo Announces the Launch of XES Sensual, a Unique CBD Sexual Wellness Product Continues Company Trend of Product Innovation in Growing Category
from Business Wire News Releases
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
from PR Newswire
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
from PR Newswire
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
from PR Newswire
Halo Announces the Launch of the Shatterizer™ Vaporizer Device
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

WHAT'S POPULAR IN THE VILLE